Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC

Summary

Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or subcutaneous disease. Patients will receive one complete cycle of therapy, consisting of local injection of plasmid IL-12 (pIL-12) followed immediately by electroporation (EP), into accessible tumor lesions. IT-pIL12-EP will be administered in Days 1, 5, and 8 of the single 28-day cycle.

Timeline

Start

2015-09

Primary completion

2018-07

Completion

2018-07

Drugs

Indications